Nofeembar 2022: Isku darka doxorubicin, vincristine, etoposide, prednisone, iyo cyclophosphamide oo leh brentuximab vedotin (Adcetris, Seagen, Inc.) waxaa ansixiyay Maamulka Cuntada iyo Dawooyinka si loogu isticmaalo carruurta iyo dadka waaweyn ee leh khatarta sare ee Hodgkin lymphoma kuwaas oo aan haysanin. helay daawayn hore (cHL). Tani waa ansixinta ugu horreysa ee brentuximab vedotin ee dhakhtarka carruurta.
Tijaabo aan kala sooc lahayn, calaamad furan, tijaabo si firfircoon loo xakameeyay ayaa loo adeegsaday si loo qiimeeyo waxtarka. Marxaladda IIB ee leh jirro badan oo ka jirta Ann Arbor, Stage IIIB, Stage IVA, iyo Stage IVB ayaa dhamaantood loo kala saaray inay yihiin khatar sare. Brentuximab vedotin oo lagu daray doxorubicin (A), vincristine (V), etoposide (E), prednisone (P), iyo cyclophosphamide (C) [brentuximab vedotin + AVEPC] ayaa la siiyay 300 bukaan, halka A+bleomycin (B)+V+ E+P+C [ABVE-PC] ayaa la siiyay 300 bukaan. Bukaannada gacanta daawaynta kasta waxay yeelan karaan ilaa 5 wareeg oo kuwan soo socda:
Prednisone 20 mg/m2 BID (maalmo 1-7), cyclophosphamide 600 mg/m2 (maalmaha 1 iyo 2), doxorubicin 25 mg/m2 (maalmaha 1 iyo 2), vincristine 1.4 mg/m2 (maalmaha 1 iyo 8), etoposide 125 mg/m2 (maalmo 1-3), iyo brentuximab vedotin 1.8 mg/kg in ka badan 30 daqiiqo (maalin (maalmo 1 iyo 2).
Badbaadada aan dhacdooyinka lahayn (EFS), oo ah wakhtiga laga bilaabo randomization ilaa ugu horrayn ee horumarka ama soo noqoshada cudurka, malignantiga labaad, ama dhimashada sabab kasta, waxay u adeegtay qiyaasta natiijada waxtarka aasaasiga ah. Labada gacan midkoodna dhexdhexaadka EFS laguma gaadhin. Marka la barbar dhigo saamiga khatarta ah ee 0.41 (95% CI: 0.25, 0.67; p=0.0002), waxaa jiray 52 dhacdooyin (17%) gacanta ABVE-PC iyo dhacdooyinka 23 (8%) ee brentuximab vedotin + gacanta AVEPC.
In paediatric patients receiving brentuximab vedotin in combination with AVEPC, neutropenia, anaemia, thrombocytopenia, febrile neutropenia, stomatitis, and infection were the most frequent Grade 3 adverse events (5%).
Carruurta da'doodu tahay 2 sano iyo wixii ka weyn, qiyaasta brentuximab vedotin ee la soo jeediyay waa 1.8 mg/kg ilaa 180 mg iyadoo lala kaashanayo AVEPC 3 toddobaad kasta ugu badnaan 5 qiyaasood.
Eeg macluumaadka dawaynta oo dhamaystiran ee Adcetris.
